Literature DB >> 14552835

BTLA: a new inhibitory receptor with a B7-like ligand.

Beatriz M Carreno1, Mary Collins.   

Abstract

The B and T lymphocyte attenuator, BTLA, is a recently discovered Ig superfamily member. BTLA engagement results in downregulation of T-cell activation, and mice deficient in BTLA show increased incidence and severity of autoimmune disorders. A novel B7 family member, B7x (B7S1, B7-H4), has been proposed as the ligand for BTLA. A B7x-Ig fusion protein inhibits T-cell activation and interleukin-2 (IL-2) production. Thus, cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and BTLA comprise an expanding set of inhibitory receptors expressed on lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552835     DOI: 10.1016/j.it.2003.08.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  22 in total

1.  A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.

Authors:  Lino C Gonzalez; Kelly M Loyet; Jill Calemine-Fenaux; Vandana Chauhan; Bernd Wranik; Wenjun Ouyang; Dan L Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

2.  B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.

Authors:  Amy E Krambeck; R Houston Thompson; Haidong Dong; Christine M Lohse; Eugene S Park; Susan M Kuntz; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

3.  DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.

Authors:  Mizuki Tomihari; Jin-Sung Chung; Hideo Akiyoshi; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

Review 4.  Immunotherapy in prostate cancer.

Authors:  Ilya Sobol; R H Thompson; Haidong Dong; Christopher Krco; Eugene D Kwon
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

5.  Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.

Authors:  Hideo Akiyoshi; Jin-Sung Chung; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2010-02-22       Impact factor: 5.422

6.  The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Authors:  Jin-Sung Chung; Makoto Bonkobara; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

Review 7.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

8.  T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province.

Authors:  Ming Liang; Jingyuan Li; Dandan Wang; Shuchen Li; Yi Sun; Tiewei Sun; Jing Zhang; Xiaoning Chen; Qiang Li; Shibo Sun
Journal:  Tumour Biol       Date:  2013-07-20

Review 9.  B7-H4's role "beyond the tumor".

Authors:  Ning Yu; Xiaomei Li; Songguo Zheng; Xiangpei Li
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 10.  Insights into the apoptotic death of immune cells in sepsis.

Authors:  Ying-yi Luan; Yong-ming Yao; Xian-zhong Xiao; Zhi-yong Sheng
Journal:  J Interferon Cytokine Res       Date:  2014-07-09       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.